[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Samuels SE, Knowles AL, Tilignac T, Debiton E, Madelmont JC, Attaix D: Protein metabolism in the small intestine during cancer cachexia and chemotherapy in mice. Cancer Res; 2000 Sep 1;60(17):4968-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein metabolism in the small intestine during cancer cachexia and chemotherapy in mice.
  • The impact of cancer cachexia and chemotherapy on small intestinal protein metabolism and its subsequent recovery was investigated.
  • Cancer cachexia was induced in mice with colon 26 adenocarcinoma, which is a small and slow-growing tumor characteristic of the human condition, and can be cured with 100% efficacy using an experimental nitrosourea, cystemustine (C6H12ClN3O4S).
  • Both healthy mice and tumor-bearing mice were given a single i.p. injection of cystemustine (20 mg/kg) 3 days after the onset of cachexia.
  • Cancer cachexia led to a reduced in vivo rate of protein synthesis in the small intestine relative to healthy mice (-13 to -34%; P < 0.05), resulting in a 25% loss of protein mass (P < 0.05), and decreased villus width and crypt depth (P < 0.05).
  • In treated mice, acute cytotoxicity of chemotherapy did not promote further wasting of small intestinal protein mass, nor did it result in further damage to intestinal morphology.
  • In contrast, mucosal damage and a 17% reduction in small intestinal protein mass (P < 0.05) were evident in healthy mice treated with cystemustine, suggesting that the effects of chemotherapy on the small intestine in a state of cancer cachexia are not additive, which was an unexpected finding.
  • Complete and rapid recovery of small intestinal protein mass in cured mice resulted from an increase in the rate of protein synthesis compared with healthy mice (23-34%; P < 0.05).
  • Northern hybridizations of mRNA encoding components of the major proteolytic systems suggested that proteolysis may not have mediated intestinal wasting or recovery.
  • A major clinical goal should be to design methods to improve small intestinal protein metabolism before the initiation of chemotherapy.
  • [MeSH-major] Adenocarcinoma / complications. Antineoplastic Agents / toxicity. Cachexia / metabolism. Colonic Neoplasms / complications. Intestine, Small / metabolism. Nitrosourea Compounds / toxicity. Proteins / metabolism
  • [MeSH-minor] Animals. Atrophy. Blotting, Northern. Cathepsin B / biosynthesis. Cathepsin B / genetics. Cathepsin B / metabolism. Eating. Gene Expression. Male. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Protein Biosynthesis. Ubiquitins / biosynthesis. Ubiquitins / genetics. Ubiquitins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10987314.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / Proteins; 0 / Ubiquitins; 79955-36-5 / N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


2. Dickson MA, Shah MA, Rathkopf D, Tse A, Carvajal RD, Wu N, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK: A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol; 2010 Nov;66(6):1113-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical activity included 2 partial responses in small bowel cancer and bladder cancer and 1 complete response in mucosal melanoma.
  • Clinical benefit was correlated with the presence of wild-type p53.
  • Of 25 patients with colorectal cancer, 11 had as best response SD for >3 m (median 6 m, range 4.2-15.4 m), despite failing ≥1 irinotecan-containing regimen.
  • CONCLUSIONS: Treatment with flavopiridol and FOLFIRI is a safe and effective regimen.
  • Clinical activity is encouraging and includes prolonged stable disease in patients with irinotecan-refractory colorectal cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2637-45 [18981292.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2527-36 [11489836.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4209-19 [11751522.001]
  • [Cites] Mol Cancer Ther. 2003 Jun;2(6):549-55 [12813134.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] Invest New Drugs. 2004 Aug;22(3):315-22 [15122079.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jun 15;201(2):589-95 [8002990.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2973-8 [8674031.001]
  • [Cites] Curr Opin Genet Dev. 1996 Feb;6(1):56-64 [8791491.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1876-83 [10430095.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):889-98 [15681535.001]
  • [Cites] Contemp Clin Trials. 2005 Apr;26(2):131-40 [15837436.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3836-45 [15897584.001]
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):249-53 [15978659.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5935-41 [16115936.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Haematologica. 2006 Mar;91(3):390-3 [16503551.001]
  • [Cites] Invest New Drugs. 2006 Jul;24(4):305-10 [16683073.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1158-65 [16600980.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5841-6 [17908977.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2312-20 [18381438.001]
  • [Cites] Clin Lung Cancer. 2008 May;9(3):160-5 [18621626.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2168-81 [11489790.001]
  • (PMID = 20953860.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA067819; United States / NCI NIH HHS / CA / R01CA67819
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Piperidines; 0 / Protein Kinase Inhibitors; 45AD6X575G / alvocidib; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS195344; NLM/ PMC2957673
  •  go-up   go-down


3. Hahn SM, Putt ME, Metz J, Shin DB, Rickter E, Menon C, Smith D, Glatstein E, Fraker DL, Busch TM: Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res; 2006 Sep 15;12(18):5464-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy.
  • PURPOSE: A phase II trial of Photofrin-mediated i.p. photodynamic therapy shown in a previous report limited efficacy and significant acute, but not chronic, toxicity.
  • A secondary aim of this trial and the subject of this report is to determine Photofrin uptake in tumor and normal tissues.
  • Photofrin uptake was measured by spectroflurometric analysis of drug extracted from tumor and normal tissues removed at surgery.
  • Differences in drug uptake among these tissues were statistically considered using mixed-effects models.
  • In normal tissues, drug uptake significantly (P<0.0001) differed as a function of seven different tissue types.
  • In the toxicity-limiting tissue of intestine, the model-based mean (SE) Photofrin level was 2.70 ng/mg (0.32 ng/mg) and 3.42 ng/mg (0.24 ng/mg) in full-thickness large and small intestine, respectively.
  • In tumors, drug uptake significantly (P=0.0015) differed as a function of patient cohort: model-based mean Photofrin level was 3.32 to 5.31 ng/mg among patients with ovarian, gastric, or small bowel cancer; 2.09 to 2.45 ng/mg among patients with sarcoma and appendiceal or colon cancer; and 0.93 ng/mg in patients with pseudomyxoma.
  • Ovarian, gastric, and small bowel cancers showed significantly higher Photofrin uptake than full-thickness large and/or small intestine.
  • However, the ratio of mean drug level in tumor versus intestine was modest (<or=2.31).
  • CONCLUSIONS: Some selectivity is found in Photofrin uptake between tumor and normal tissues of the peritoneal cavity, but absolute differences in drug uptake relative to toxicity-limiting normal tissues (intestine) are small.
  • This narrow differential in drug selectivity likely contributes to a narrow window in therapeutic application, which has been previously reported.
  • [MeSH-minor] Biopsy. Cohort Studies. Female. Gastrointestinal Neoplasms / drug therapy. Humans. Injections, Intraperitoneal. Models, Biological. Organ Specificity. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000681.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA-87971; United States / NCI NIH HHS / CA / R01 CA-85831
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


Advertisement
4. Tadmor T, Rainis T, Bejar J, Attias D, Lavy A: Primary duodenal mucosa-associated lymphoid tissue (MALT) lymphoma--a rare presentation of gastric outlet obstruction. Can J Gastroenterol; 2007 Jun;21(6):393-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary duodenal mucosa-associated lymphoid tissue (MALT) lymphoma--a rare presentation of gastric outlet obstruction.
  • Malignant lymphoma of mucosa-associated lymphoid tissue (MALT) can arise in a variety of anatomical sites.
  • The majority of these tumors arise in the stomach, with fewer than 30% arising in the small intestine.
  • Primary duodenal MALT lymphoma is a very rare neoplasm.
  • The patient was successfully treated with a combination of chemotherapy and rituximab.
  • [MeSH-major] Duodenal Neoplasms / complications. Gastric Outlet Obstruction / etiology. Lymphoma, B-Cell, Marginal Zone / complications

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):536-9 [10685764.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1979-83 [15668468.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Aug;14(8):893-6 [12172414.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):271-7 [14531908.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):895-8 [6547634.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Histopathology. 1987 May;11(5):445-62 [3497084.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):309-15 [3334966.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Gastroenterology. 1992 May;102(5):1628-38 [1568573.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • [Cites] J Clin Pathol. 1994 May;47(5):436-9 [8027397.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Gastrointest Endosc. 1995 Mar;41(3):258-61 [7789690.001]
  • [Cites] Gastroenterology. 1996 Dec;111(6):1674-8 [8942749.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • (PMID = 17571175.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2658124
  •  go-up   go-down


5. Shehata M, Chu F, Saunders V, Kam PC, Links M, Morris DL: Peritoneal carcinomatosis from colorectal cancer and small bowel cancer treated with peritonectomy. ANZ J Surg; 2006 Jun;76(6):467-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis from colorectal cancer and small bowel cancer treated with peritonectomy.
  • BACKGROUND: This study aims to assess the survival of patients who underwent peritonectomy, to assess the morbidity and mortality associated with the procedure and to review the published reports on the survival of patients with peritoneal spread of colorectal cancer (CRC).
  • METHODS: Peritonectomy involves resection of all visible peritoneal tumour and is followed by heated intraperitoneal chemotherapy.
  • Peritonectomy with heated intraperitoneal chemotherapy is associated with a 3-year survival of 30-50% in patients with low peritoneal cancer index (PCI) with peritoneal carcinomatosis from CRC.
  • This study describes 22 patients with peritoneal spread of gastrointestinal cancer treated with peritonectomy between 1996 and March 2005.
  • Twenty of these patients had primary colorectal cancer and two patients had primary small bowel cancer.
  • We found that those patients with all macroscopic residual tumour removed at the end of the procedure (completeness of cancer resection, CCR O) had improved 24-month survival compared with patients in whom there was incomplete tumour resection (53.3% survival vs 22.2%, respectively, P = 0.024).
  • [MeSH-major] Carcinoma / mortality. Carcinoma / surgery. Intestinal Neoplasms / pathology. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / surgery. Postoperative Complications
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16768770.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


6. Han SL, Cheng J, Zhou HZ, Guo SC, Jia ZR, Wang PF: Surgically treated primary malignant tumor of small bowel: a clinical analysis. World J Gastroenterol; 2010 Mar 28;16(12):1527-32
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgically treated primary malignant tumor of small bowel: a clinical analysis.
  • AIM: To evaluate the clinical presentation, treatment and survival of patients with primary malignant tumor of small bowel (PMTSB).
  • RESULTS: The most common initial clinical features of the patients were intermittent abdominal discomfort or vague abdominal pain (67.4%), abdominal mass (31.2%), bowel obstruction (24.1%), hemotochezia (21.3%), jaundice (16.3%), fever (14.2%), coexistence of bowel perforation and peritonitis (5.7%), coexistence of gastrointestinal bleeding and shock (5.0%), and intraabdominal bleeding (1.4%).
  • Ileum was the most common site of tumor (44.7%), followed by jejunum (30.5%) and duodenum (24.8%).
  • Segmental bowel resection (n = 81) was the most common surgical procedure, followed by right hemi-colectomy (n = 15), pancreaticoduodenectomy (n = 10), and others (n = 19).
  • Twenty-seven adenocarcinoma patients and 13 malignant lymphoma patients received adjuvant chemotherapy with 5-fluorouracil and cyclophosphamide, adriamycin, vincristine and prednisone, respectively.
  • The median survival time of PMTSB patients was 20.3 mo.
  • Gastrointestinal stromal tumor was observed in 80.0% (20/25), 72.0% (18/25) and 36.0% (9/25) of the patients, respectively.
  • Malignant lymphoma was demonstrated in 69.2% (9/13), 30.8% (4/13) and 0% (0/13) of the patients, respectively.
  • CONCLUSION: En bloc resection is the principal therapy for most PMTSB and chemotherapy is the important treatment modality for malignant lymphoma and other malignant tumors of small bowel which cannot be radically removed.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoid Tumor / surgery. Digestive System Surgical Procedures. Gastrointestinal Stromal Tumors / surgery. Intestinal Neoplasms / surgery. Intestine, Small / surgery. Lymphoma / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):731-41 [15966194.001]
  • [Cites] Cancer Imaging. 2006;6:209-12 [17208678.001]
  • [Cites] World J Gastroenterol. 2007 Jan 21;13(3):432-7 [17230614.001]
  • [Cites] Ann Diagn Pathol. 2007 Feb;11(1):39-45 [17240306.001]
  • [Cites] Chirurgia (Bucur). 2006 Sep-Oct;101(5):477-81 [17278638.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Mar;19(2):143-9 [17355111.001]
  • [Cites] Arch Surg. 2007 Mar;142(3):229-35 [17372046.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):129-34 [17419246.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2263-9 [17549572.001]
  • [Cites] Arch Surg. 2009 Jul;144(7):670-8 [19620548.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Am J Surg. 2000 Jan;179(1):37-41 [10737576.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):727-32 [11462914.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Aug;57(2):169-83 [12153595.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):469-81 [14713260.001]
  • [Cites] Int Surg. 2004 Jan-Mar;89(1):21-6 [15085993.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] AJR Am J Roentgenol. 1989 May;152(5):995-8 [2705358.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1994 Feb;15(1):46-50 [8082141.001]
  • [Cites] Ann Surg Oncol. 1995 Jan;2(1):26-31 [7834450.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):262-7 [9060581.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12):1153-8 [9373284.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1440-4 [10424748.001]
  • [Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]
  • (PMID = 20333796.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2846261
  •  go-up   go-down


7. Kanemoto K, Kurishima K, Ishikawa H, Shiotani S, Satoh H, Ohtsuka M: Small intestinal metastasis from small cell lung cancer. Intern Med; 2006;45(16):967-70
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small intestinal metastasis from small cell lung cancer.
  • A 71-year-old man who had small cell lung cancer was referred to our institution.
  • Before starting chemotherapy, anemia progressed and stool examination was positive for occult blood.
  • An abdominal computed tomography scan with contrast medium enhancement of the gastrointestinal tract disclosed a small intestinal tumor.
  • Histological examination after the surgery confirmed that the tumor was metastasis of lung cancer.
  • Although clinically apparent metastases of lung cancer to the small intestine are rare and are reported to have a poor prognosis, early detection and intervention might enhance the chance of survival.
  • [MeSH-major] Carcinoma, Small Cell / secondary. Intestinal Neoplasms / secondary. Intestine, Small. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Male. Survival. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16974060.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Liu ZF, Jiao SC, Yang JL, Dai GH: [Clinical research of 120 cases of primary small intestine malignant tumor]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar;30(3):602-4, 607

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical research of 120 cases of primary small intestine malignant tumor].
  • OBJECTIVE: To study the clinical and pathological features, diagnosis, therapy and prognosis of primary small intestine malignant tumor.
  • METHODS: A retrospective analysis was performed on the clinical data from the 120 cases of primary small intestine malignant tumor.
  • Most tumors originated in the duodenum (54.1%), and adenocarcinoma (55.8%) was the main pathological type.
  • The median survival time of the patients was 19.2 months and the 1-year survival rate was 55.4%.
  • Chemotherapy did not seem to significantly improve the 1-year survival rate of the patients (P=0.842).
  • CONCLUSION: Primary small intestine malignant tumors lack specific clinical manifestations and surgical resection should be performed as early as possible.
  • [MeSH-major] Adenocarcinoma. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / surgery. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20335150.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Higashi D, Ishibashi Y, Tamura T, Nii K, Egawa Y, Koga M, Tomiyasu T, Harimura T, Tanaka R, Futatsuki R, Noda S, Futami K, Maekawa T, Takaki Y, Hirai F, Matsui T: Clinical features of and chemotherapy for cancer of the small intestine. Anticancer Res; 2010 Aug;30(8):3193-7
Genetic Alliance. consumer health - Small intestine cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of and chemotherapy for cancer of the small intestine.
  • BACKGROUND: Cancer of the small intestine is a rare disease, and its clinical features have not been clearly elucidated.
  • Techniques such as double balloon endoscopy and capsule endoscopy allow the preoperative diagnosis of cancer of the small intestine, but this cancer is often detected at an advanced state and in many cases postoperative chemotherapy is required.
  • This study evaluated the pre- and postoperative clinical course of cancer of the small intestine and the effectiveness of chemotherapy.
  • PATIENTS AND METHODS: Patients who underwent surgery for cancer of the small intestine in this Department from July 1985 to December 2008 were included in this study.
  • Duodenal cancer has vastly different origins, methods of diagnosis, and surgical procedures, so this form of cancer was excluded.
  • There were 8 cases of jejunal or ileal cancer treated during the study period.
  • The pre- and postoperative course of these cases was reviewed, as well as the effectiveness of chemotherapy in cases of recurrence.
  • Six patients underwent a partial resection of the small intestine, and a right hemicolectomy, and a bypass were performed in one case each.
  • The tumor type according to Borrmann's classification indicated that 5 tumors were type 2, 2 were type 3, and 1 was type 5; the mean tumor size was 6.3±5.3 (2.5-18.0) cm.
  • Six patients underwent postoperative chemotherapy.
  • One patient underwent adjuvant chemotherapy of, and 5 patients with recurring or advanced cancer underwent therapeutic chemotherapy of.
  • The course of chemotherapy for the 5 patients with recurrent or advanced cancer resulted in 4 patients with progressive disease (PD) and 1 with stable disease (SD).
  • CONCLUSION: The basic treatment for cancer of the small intestine is surgical resection.
  • Palliative surgery and chemotherapy are considered in cases where resection is not possible or the cancer recurs.
  • Nevertheless, there is no established regimen for such chemotherapy.
  • Cancer of the small intestine is currently being treated with chemotherapy based on the treatment strategies for colon cancer, but there are few reports of its success.
  • Chemotherapy was unsuccessful in treating any of the patients with recurring or advanced cancer reviewed in this report.
  • The diagnosis must therefore be improved and postoperative chemotherapy will be needed to treat cancer of the small intestine given its increasing incidence, and therefore physicians are working as quickly as possible to establish an optimal treatment regimen.
  • [MeSH-major] Intestinal Neoplasms / drug therapy. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871040.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS: Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg; 2009 Jan;249(1):63-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.
  • BACKGROUND: Previous studies have shown an increasing incidence of small bowel tumors in the United States.
  • Our objective was to assess this increase by examining changes in histology-specific incidence, treatment, and survival.
  • METHODS: Patients with small bowel malignancies were identified from the National Cancer Data Base (NCDB, 1985-2005) and the Surveillance Epidemiology and End Results (SEER, 1973-2004) database.
  • Treatment and survival trends over time were examined using the National Cancer Data Base.
  • Regression models were developed to assess survival over time.
  • RESULTS: Sixty-seven thousand eight hundred forty-three patients were identified with small bowel malignancies: 37.4% carcinoid, 36.9% adenocarcinomas, 8.4% stromal tumors, and 17.3% lymphomas.
  • Adjuvant chemotherapy utilization for adenocarcinoma increased from 8.1% in 1985 to 23.8% in 2005 (P < 0.0001).
  • Treatment over time was generally unchanged for lymphoma and stromal tumors.
  • Five-year survival after resection remained unchanged over time for all histologic subtypes even after adjusting for changes in patient demographics, tumor characteristics, and treatment approaches.
  • CONCLUSIONS: The overall incidence of small intestine malignancies has increased considerably, primarily because of carcinoid tumors which are now the most common small bowel cancer.
  • With current treatments, survival has remained relatively unchanged over the last 20 years.
  • Novel therapeutic options need to be investigated.
  • [MeSH-major] Intestinal Neoplasms. Intestine, Small
  • [MeSH-minor] Aged. Female. Humans. Incidence. Male. Middle Aged. Survival Rate. Time Factors. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106677.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Ogata Y, Yamaguchi K, Sasatomi T, Uchida S, Akagi Y, Shirouzu K: [Treatment and outcome in small bowel cancer]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1454-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and outcome in small bowel cancer].
  • In adenocarcinoma of the small intestine, delays in diagnosis are frequent, and the majority of patients present with advanced- stage disease and either lymph node involvement or distant metastatic disease.
  • Surgical resection is a mainstay in treatment of this disease, but the role of adjuvant therapy is unclear.
  • Recent retrospective and prospective studies have helped to clarify the optimal chemotherapy approach for advanced small bowel adenocarcinoma.
  • Further clinical studies on this rare type of tumor are needed.
  • The 72nd Japanese Society for Cancer of the Colon and Rectum have conducted a retrospective review of Japanese patients with adenocarcinoma of the jejunum or ileum.
  • The data indicated that although not statistically significant, there was a trend in median overall survival favoring the chemotherapy for advanced jejunal or ileal adenocarcinoma (17 months vs. 8 months, p=0.114).
  • [MeSH-major] Adenocarcinoma / therapy. Intestinal Neoplasms / therapy. Intestine, Small
  • [MeSH-minor] Combined Modality Therapy. Humans. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716869.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


12. Chua TC, Koh JL, Yan TD, Liauw W, Morris DL: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. J Surg Oncol; 2009 Aug 1;100(2):139-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma.
  • BACKGROUND: Small bowel adenocarcinoma is a rare malignancy that presents both a diagnostic and therapeutic challenge.
  • We review our experience with small bowel peritoneal carcinomatosis following treatment with cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC).
  • METHODS: From a prospective database of CRS and PIC, seven patients were identified to have undergone treatment for small bowel peritoneal carcinomatosis with CRS and hyperthermic intraperitoneal chemotherapy (Mitomycin C) and early postoperative intraperitoneal chemotherapy (5FU).
  • Tumor histology of poorly differentiated adenocarcinoma with signet ring, lymphovascular invasion and perineural invasion appeared to be associated with a poor outcome.
  • CONCLUSION: Cytoreductive surgery and perioperative intraperitoneal chemotherapy is a treatment option for small bowel cancer peritoneal carcinomatosis with encouraging survival results.
  • [MeSH-major] Adenocarcinoma / therapy. Hyperthermia, Induced. Ileal Neoplasms / therapy. Jejunal Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / therapy. Prospective Studies

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544356.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Toyokawa A, Nakajima T, Inui K, Yamashita H, Gon H, Kanemitsu K, Tanaka K, Tsukamoto T, Hamabe Y, Ishida T: [A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer]. Gan To Kagaku Ryoho; 2009 Jul;36(7):1167-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer].
  • A 50-year-old man undergoing operations for sigmoid colon cancer, small intestine invasion, and liver metastasis was given adjuvant chemotherapy postoperatively.
  • During the course, lung, brain and bone metastasis were found, FOLFIRI therapy was started.
  • Fifth FOLFIRI therapy was performed, but on the night of the next day, he was transported on an emergency basis to our hospital because of a coma.
  • Laboratory examination revealed hyperammonemia, so aminoleban was started for its treatment.
  • Hyperammonemia should be taken into account as a differential diagnosis in the disturbance of consciousness in chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Neoplasms / drug therapy. Hyperammonemia / chemically induced
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Consciousness Disorders / chemically induced. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged

  • Genetic Alliance. consumer health - Hyperammonemia.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620810.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


14. Lee T, Noda E, Maeda K, Inoue T, Nagahara H, Amano R, Kubo N, Tanaka H, Muguruma K, Takashima T, Yamada N, Yashiro M, Onoda N, Sawada T, Nakata B, Ohira M, Ishikawa T, Hirakawa K: [Two cases of the primary small intestine cancer successfully treated with S-1 and UFT/LV therapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2789-91
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of the primary small intestine cancer successfully treated with S-1 and UFT/LV therapy].
  • The primary small intestinal cancer is rare in gastrointestinal cancer, and there are much advanced/recurrent cases.
  • However, there were a few case reports about chemotherapy for advanced or recurrent small intestinal cancer, and a treatment resume was inconsistent.
  • We reported that S-1 and UFT/LV therapy was effective with the two cases as an oral chemotherapy for the primary small intestinal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Jejunal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Drug Combinations. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Oxonic Acid / administration & dosage. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Small intestine cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224714.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5VT6420TIG / Oxonic Acid; Q573I9DVLP / Leucovorin; 1-UFT protocol
  •  go-up   go-down


15. Kobayashi K, Yano S, Kato K, Tatsukawa T, Ikeda T, Tokushima T: [Case with double primary cancers occurring synchronously in both the lung and jejunum diagnosed according to TTF-1 expression]. Nihon Kokyuki Gakkai Zasshi; 2005 Feb;43(2):84-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case with double primary cancers occurring synchronously in both the lung and jejunum diagnosed according to TTF-1 expression].
  • He received chemotherapy and radiotherapy.
  • The lymph node was near by the Treitz' ligament, and a tumor measuring 30 mm was observed in the jejunum.
  • The differential diagnosis between small intestine metastasis and primary small intestine cancer was difficult.
  • As adenocarcinoma of the jejunum was negative for TTF-1 in immunohistochemical staining and adenocarcinoma of the lung was positive, we diagnosed this patient as having primary jejunal cancer.
  • We report this rare case of double cancer involving the lung and jejunum.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Intestine, Small. Jejunal Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Nuclear Proteins / analysis. Transcription Factors / analysis
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770938.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


16. Takahashi K, Funayama Y, Tokumura H, Tanda S, Maekawa H, Chiba T, Toshima T, Fukuyama S, Musha H, Matsumura N, Sasaki H, Yasumoto A: [A case of multiple metachronous metastases of colon cancer to the small intestine preoperatively diagnosed by double balloon enteroscopy and radically resected]. Nihon Shokakibyo Gakkai Zasshi; 2010 Feb;107(2):233-40
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of multiple metachronous metastases of colon cancer to the small intestine preoperatively diagnosed by double balloon enteroscopy and radically resected].
  • The patient was a 75-year-old woman who had undergone resection of a transverse colon cancer two years before.
  • She had anemia and intestinal obstruction, and a diagnosis of multiple metastases to the small intestine was made by double balloon enteroscopy.
  • Adjuvant FOLFOX chemotherapy was given, achieving a 26-month disease-free survival.
  • The double balloon enteroscopy was useful in the definitive diagnosis of this case, and aggressive resection with adjuvant chemotherapy contributed to the good outcome.
  • [MeSH-major] Colonic Neoplasms / pathology. Endoscopy, Gastrointestinal / methods. Ileal Neoplasms / secondary. Jejunal Neoplasms / secondary

  • Genetic Alliance. consumer health - Small intestine cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20134126.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 26
  •  go-up   go-down


17. Yonemura Y, Tsukiyama G, Miyata R, Sako S, Endou Y, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M, Hagiwara A, Li Y: Indication of peritonectomy for peritoneal dissemination. Gan To Kagaku Ryoho; 2010 Nov;37(12):2306-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 521 patients with peritoneal carcinomatosis (PC) were treated by peritonectomy and perioperative chemotherapy.
  • Each of the 95, 58, 316, 31, 10 and 11 patients were from gastric, colorectal, appendiceal, ovarian, small bowel cancer and mesothelioma, respectively.
  • Peritonectomy was performed with a radical resection of the primary tumor and all gross PC with involved organs, peritoneum, or tissue that was deemed technically feasible and safe for the patient.
  • The survival of gastric cancer patients with a PCI score ≤ 6 was significantly better than those with a PCI score ≥ 7.
  • In appendiceal neoplasm, patients with PCI score less than 28 showed significantly better survival than those with PCI score greater than 29.
  • The survival of colorectal cancer patients with a PCI score ≥ 11 was significantly poorer than those with a PCI score ≤ 10.
  • Among the various prognostic factors in appendiceal neoplasm and gastric cancer patients, CC-0 complete cytoreduction was the most important independent prognostic factor.
  • Peritonectomy is done to remove macroscopic disease and perioperative intraperitoneal chemotherapy to eradicate microscopic residual disease aiming to remove disease completely with a single procedure.
  • Peritonectomy combined with perioperative chemotherapy may achieve long-term survival in a selected group of patients with PC.
  • [MeSH-major] Carcinoma / surgery. Peritoneal Neoplasms / surgery. Peritoneum / surgery
  • [MeSH-minor] Aged. Appendiceal Neoplasms / drug therapy. Appendiceal Neoplasms / surgery. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Combined Modality Therapy. Female. Humans. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / surgery. Male. Mesothelioma / drug therapy. Mesothelioma / surgery. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery. Postoperative Complications. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224556.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Guckenberger M, Flentje M: Late small bowel toxicity after adjuvant treatment for rectal cancer. Int J Colorectal Dis; 2006 Apr;21(3):209-20
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late small bowel toxicity after adjuvant treatment for rectal cancer.
  • BACKGROUND: For locally advanced rectal cancer surgery as sole treatment results in poor local control and survival.
  • After adjuvant radiotherapy for locally advanced rectal cancer, small bowel toxicity has been the most frequent and serious side effect.
  • The gain in survival and local control was accompanied by severe late chronic toxicity reducing the benefit of adjuvant treatment.
  • REVIEW: Clinical factors, pathology and treatment of late small bowel toxicity after adjuvant radiotherapy for locally advanced rectal cancer will be discussed.
  • This review will focus on different surgical and radiotherapeutic means reducing the risk of late small bowel damage.
  • [MeSH-major] Chemotherapy, Adjuvant / adverse effects. Intestinal Diseases / chemically induced. Intestine, Small / drug effects. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Diarrhea / chemically induced. Hemorrhage / chemically induced. Humans. Intestinal Obstruction / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Oct;10(10):1885-90 [6386762.001]
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Oncology (Williston Park). 1988 Aug;2(8):21-5, 28-9 [3275055.001]
  • [Cites] World J Surg. 1986 Apr;10(2):171-88 [3518250.001]
  • [Cites] Am J Clin Oncol. 1982 Apr;5(2):189-94 [7091042.001]
  • [Cites] Am Surg. 1992 Feb;58(2):132-5 [1550305.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1130-5 [9278661.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Oct;9(10):1445-50 [6415005.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14 ):980-7 [9091798.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Feb 1;28(3):597-603 [8113102.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Eur J Surg Oncol. 1992 Oct;18(5):487-93 [1426301.001]
  • [Cites] Surg Gynecol Obstet. 1984 Aug;159(2):162-3 [6463828.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):51-7 [9747819.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):455-9 [11567821.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):49-55 [2191763.001]
  • [Cites] Surg Gynecol Obstet. 1985 Apr;160(4):365-6 [3983803.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1213-36 [7713784.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Sep;12(9):1565-73 [3759581.001]
  • [Cites] Surg Gynecol Obstet. 1983 Sep;157(3):269-71 [6612575.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):99-109 [7642437.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Mar;5(3):373-82 [110745.001]
  • [Cites] Cancer. 1992 Aug 1;70(3):581-4 [1623474.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1995;7(3):188-92 [7547523.001]
  • [Cites] J Pathol. 2003 Jul;200(4):500-3 [12845617.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):1039-48 [8751414.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):995-8 [10705022.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Jan;10(1):55-62 [6698825.001]
  • [Cites] Am Surg. 1994 Jul;60(7):473-82; discussion 482-3 [8010560.001]
  • [Cites] Acta Oncol. 2001;40(8):958-67 [11845961.001]
  • [Cites] Cancer. 1991 Dec 15;68(12):2545-9 [1657360.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51 [9593234.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):319-24 [9788410.001]
  • [Cites] Cancer. 1977 Mar;39(3):1243-6 [912657.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):817-25 [10098437.001]
  • [Cites] Br J Surg. 1973 Oct;60(10 ):814-8 [4748388.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Aug;15(5):233-6 [12924451.001]
  • [Cites] Strahlenther Onkol. 2000 Mar;176(3):105-11 [10742830.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):549-57 [1548520.001]
  • [Cites] Am J Gastroenterol. 1990 Feb;85(2):121-8 [2301333.001]
  • [Cites] Surg Gynecol Obstet. 1981 Dec;153(6):896-900 [7302817.001]
  • [Cites] Oncology (Williston Park). 1998 Jan;12(1):51-4; discussion 54, 60, 62, passim [9474587.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):885-93 [8478241.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1409-16 [7751886.001]
  • [Cites] Am Surg. 1994 Apr;60(4):282-6 [8129251.001]
  • [Cites] Surgery. 1986 Feb;99(2):133-9 [3484844.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1271-80 [11728687.001]
  • [Cites] Acta Oncol. 1999;38(1):23-32 [10090685.001]
  • [Cites] FASEB J. 2004 May;18(7):816-27 [15117886.001]
  • [Cites] Dis Colon Rectum. 1993 Jun;36(6):564-72 [8500374.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):67-76 [9300741.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Gastroenterology. 1977 Nov;73(5):1093-7 [908489.001]
  • [Cites] J Am Coll Surg. 1999 Dec;189(6):611-24 [10589598.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] J Chir (Paris). 1981 Apr;118(4):221-9 [7228928.001]
  • [Cites] Dis Colon Rectum. 1984 Feb;27(2):89-92 [6697836.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1977 Nov-Dec;2(11-12):1069-74 [599058.001]
  • [Cites] Radiother Oncol. 2003 Jun;67(3):345-9 [12865185.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):469-76 [2394624.001]
  • [Cites] Obstet Gynecol. 1977 Mar;49(3):333-8 [840462.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):968-76 [8780533.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] Dis Colon Rectum. 2001 Dec;44(12):1772-7 [11742161.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1193-8 [10613312.001]
  • [Cites] Radiology. 1974 Sep;112(3):699-703 [4843305.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):896-902 [11550163.001]
  • [Cites] Dis Colon Rectum. 1988 Jan;31(1):17-21 [2835216.001]
  • [Cites] Radiat Res. 2004 Mar;161(3):299-311 [14982484.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):835-40 [10386640.001]
  • [Cites] N Engl J Med. 1985 Jun 6;312(23 ):1465-72 [2859523.001]
  • [Cites] Arch Surg. 2000 Oct;135(10):1212-7 [11030884.001]
  • [Cites] Strahlenther Onkol. 2000 Apr;176(4):161-7 [10812388.001]
  • [Cites] Am J Clin Oncol. 1988 Feb;11(1):25-33 [2829614.001]
  • [Cites] Am J Obstet Gynecol. 1977 Aug 1;128(7):767-71 [879244.001]
  • [Cites] Radiother Oncol. 1994 Aug;32(2):116-23 [7972904.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1336-41 [9369109.001]
  • [Cites] Radiology. 1979 Aug;132(2):479-82 [461811.001]
  • [Cites] Am J Surg. 2001 Sep;182(3):237-42 [11587684.001]
  • [Cites] Strahlenther Onkol. 1995 Aug;171(8):437-43 [7652666.001]
  • (PMID = 16052309.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 89
  •  go-up   go-down


19. Naeim A, Dy SM, Lorenz KA, Sanati H, Walling A, Asch SM: Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol; 2008 Aug 10;26(23):3903-10
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based recommendations for cancer nausea and vomiting.
  • The experience of patients living with cancer and being treated with chemotherapy often includes the symptoms of nausea and vomiting.
  • To provide a framework for high-quality management of these symptoms, we developed a set of key targeted evidence-based standards through an iterative process of targeted systematic review, development, and refinement of topic areas and standards and consensus ratings by a multidisciplinary expert panel as part of the RAND Cancer Quality-Assessing Symptoms Side Effects and Indicators of Supportive Treatment Project.
  • For nausea and vomiting, key clinical standards included screening at the initial outpatient and inpatient visit, prophylaxis for acute and delayed emesis in patients receiving moderate to highly emetic chemotherapy, and follow-up after treatment for nausea and vomiting symptoms.
  • In addition, patients with cancer and small bowel obstruction were examined as a special subset of patients who present with nausea and vomiting.
  • The standards presented here for preventing and managing nausea and vomiting in cancer care should be incorporated into care pathways and should become the expectation rather than the exception.
  • [MeSH-major] Antiemetics / therapeutic use. Antineoplastic Agents / adverse effects. Dexamethasone / therapeutic use. Intestinal Obstruction / complications. Morpholines / therapeutic use. Nausea. Neoplasms / drug therapy. Quality Assurance, Health Care. Serotonin 5-HT3 Receptor Antagonists. Vomiting


20. Qureshi I, Awad ZT: Predictors of failure of the laparoscopic approach for the management of small bowel obstruction. Am Surg; 2010 Sep;76(9):947-50
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of failure of the laparoscopic approach for the management of small bowel obstruction.
  • Small bowel obstruction (SBO) is a common cause of hospital admission.
  • Twenty-three consecutive patients underwent diagnostic laparoscopy with curative intent for treatment of SBO by a single surgeon over a 3-year period.
  • The causes of obstruction included adhesive band in 16 patients; and small bowel lymphoma, metastatic esophageal cancer, small bowel gangrene, Meckel diverticulum, gallstones ileus, and incarcerated incisional hernia in two.
  • Using the Fisher two-sided test, no significant predictor for conversion was identified using gender, American Society of Anesthesiologists class, previous bowel obstruction, history of adhesiolysis, abdominal distention, pelvic surgeries, chemotherapy, radiation, malignancy, chronic obstructive pulmonary disease, asthma, coronary artery disease, hypertension, or hypercholesterolenemia.
  • The Wilcoxon two-sided test did not show significance for age, weight, number of previous abdominal surgeries, or small bowel diameter.
  • [MeSH-major] Intestinal Obstruction / surgery. Laparoscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Comorbidity. Female. Humans. Laparotomy. Length of Stay. Male. Middle Aged. Retrospective Studies. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20836340.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Omura K: [Specialized nutrition support for the patients with advanced or recurrent carcinoma of the gastrointestinal tract]. Nihon Geka Gakkai Zasshi; 2004 Feb;105(2):228-32
Hazardous Substances Data Bank. CYANOCOBALAMIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Routine parenteral nutrition for cancer patients who undergo chemotherapy results in no benefit and troublesome complications such as catheter sepsis.
  • Consequently, it is important to provide sufficient and proper specialized nutritional support to patients who need it, taking into account the pathologic status resulting from malignant disease.
  • This phenomenon should be avoided when 5-fluorouracil is used with reduced folate in cancer chemotherapy.
  • The indications for specialized nutritional support for patients with advanced or recurrent carcinoma of the gastrointestinal tract are the same as for malnourished patients without cancer.
  • The initial dose and formula of nutrition for cancer patients with malnutrition and various metabolic disorders should be calculated to avoid overloading.
  • The placement of a central venous catheter to prevent the toxicity of chemotherapy or for venous access is contraindicated.
  • If any bowel obstruction occurs in the small intestine and/or colon, it is necessary to discuss the efficacy of surgery to resolve the obstruction.
  • [MeSH-major] Gastrointestinal Neoplasms / drug therapy. Nutritional Support / methods
  • [MeSH-minor] Enteral Nutrition. Folic Acid / administration & dosage. Folic Acid Deficiency / etiology. Humans. Neoplasm Recurrence, Local. Nutrition Assessment. Nutrition Disorders / etiology. Vitamin B 12 / administration & dosage. Vitamin B 12 Deficiency / etiology

  • MedlinePlus Health Information. consumer health - Nutritional Support.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15027166.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  • [Number-of-references] 12
  •  go-up   go-down


22. Hong SH, Koh YH, Rho SY, Byun JH, Oh ST, Im KW, Kim EK, Chang SK: Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol; 2009 Jan;39(1):54-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome.
  • BACKGROUND: Malignant small intestine tumor accounts for 0.1-0.3% of all malignancies.
  • METHODS: We conducted retrospective analysis for the patients with the small intestine adenocarcinoma to explore the clinical characteristics and prognosis.
  • All patients with adenocarcinoma of small intestine diagnosed between March 1997 and March 2007 in the Catholic Medical Center in Korea were identified through the cancer registry.
  • The medical records were reviewed for patient characteristics, treatment and outcome data.
  • Twenty-six patients (49.0%) underwent curative resection and 13 patients receiving adjuvant chemotherapy.
  • Fifteen patients received palliative chemotherapy.
  • Median survival of patients received palliative chemotherapy was 8.0 months (95% CI: 3.5-12.4).
  • CONCLUSIONS: The prognosis of primary adenocarcinoma of small intestine was poor, especially in cases where curative resection could not to be performed.
  • Further study on the methods for early detection and effective systemic chemotherapy should be investigated.
  • [MeSH-major] Adenocarcinoma / pathology. Intestinal Neoplasms / pathology. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Korea. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18997182.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


23. Schoemaker NE, Kuppens IE, Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, Schellens JH: Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. Cancer Chemother Pharmacol; 2005 Mar;55(3):263-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumours were predominantly colorectal (30) together with 10 other gastrointestinal, 2 breast, 2 small cell lung and 1 ovarian.
  • All but three patients had received prior chemotherapy.
  • There were two documented partial responses, one in a patient with cancer of the small intestine and the other in a patient with colon cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Drug Administration Schedule. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / adverse effects. Female. Gastrointestinal Tract / drug effects. Humans. Male. Maximum Tolerated Dose. Middle Aged. Topoisomerase I Inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592838.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


24. Sharykina NI, Bukhtiarova TA, Kudriavtseva IG, Pavlovskaia GP: [Cytostatic effects of bifolar and chlofiden. Effect on protein synthesis and cell cycle]. Ukr Biokhim Zh (1999); 2004 Jan-Feb;76(1):123-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was shown that the preparations inhibited protein synthesis in normal and malignant tissues.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Ethylamines / pharmacology. Mitosis / drug effects. Neoplasm Proteins / biosynthesis. Phosphoramide Mustards / pharmacology. Protein Biosynthesis / drug effects. Sarcoma, Experimental / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Intestine, Small / drug effects. Intestine, Small / metabolism. Intestine, Small / pathology. Liver / drug effects. Liver / metabolism. Liver / pathology. Mice. Neoplasm Transplantation. Rats. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909427.001).
  • [Journal-full-title] Ukraïnsʹkyĭ biokhimichnyĭ z︠h︡urnal (1999 )
  • [ISO-abbreviation] Ukr Biokhim Zh (1999)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chlofiden; 0 / Ethylamines; 0 / Neoplasm Proteins; 0 / Phosphoramide Mustards; 1950-04-5 / Preparation F-11
  •  go-up   go-down


25. Sakakibara T, Kurasawa T, Narumi K, Kamano T, Tsurumaru M: T-cell malignant lymphoma of the ileum causing ileac fistulas: report of a case. Surg Today; 2002;32(6):536-40
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell malignant lymphoma of the ileum causing ileac fistulas: report of a case.
  • Upper and lower gastrointestinal examinations did not reveal any abnormal findings, but an abdominal aortic aneurysm was diagnosed by computed tomography, and thus was determined to be the source of the pain.
  • The patient was referred to our hospital to undergo a grafting operation; however, a laparotomy performed in July 1997 revealed an unexpected small intestinal tumor, and therefore a partial ileectomy between 15 and 70cm in an oral direction from the terminal ileum was carried out instead.
  • Histopathological and genetic examinations demonstrated diffuse small malignant lymphocytic T-cell lymphomas of the ileum invading all layers.
  • Metastasis of the facial skin and local recurrence were recognized 5 months later, and chemotherapy with THP-COP and ESHAP only resulted in progressive disease.
  • An ileac fistula was found to have formed between the intestine and abdominal wall in March 1998, and the patient died in May 1998.
  • [MeSH-major] Ileal Neoplasms / complications. Intestinal Fistula / etiology. Lymphoma, T-Cell / complications
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12107782.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down


26. Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, Shivdasani RA: High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer; 2008 Jul;47(7):591-603
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss.
  • Carcinoid tumors of the small intestine are characterized by an indolent clinical course, secretion of neuropeptides, and resistance to standard cytotoxic chemotherapy.
  • To evaluate the molecular events underlying carcinoid tumorigenesis, we used high-resolution arrays of single nucleotide polymorphisms to study chromosomal gains and losses in 24 primary and metastatic small bowel carcinoid tumors derived from 18 patients.
  • The amplitude of observed gains was modest in comparison to those reported in some other tumor types.
  • One focal region of recurrent gain on 14q mapped to the locus of the gene encoding the antiapoptotic protein DAD1, and immunohistochemical staining confirmed DAD1 protein expression in tumor samples.
  • This detailed study of an uncommon neoplasm provides a basis to investigate putative oncogenes and tumor suppressor genes in intestinal carcinoid tumors.
  • [MeSH-major] Chromosome Aberrations. Intestinal Neoplasms / genetics. Intestine, Small. Liver Neoplasms / genetics. Malignant Carcinoid Syndrome / genetics. Neoplasm Recurrence, Local / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18383209.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / DAD1 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


27. Quintas-Cardama A, Fraga M, Antunez J, Forteza J: Primary extramedullary myeloid tumor of the breast: a case report and review of the literature. Ann Hematol; 2003 Jul;82(7):431-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extramedullary myeloid tumor of the breast: a case report and review of the literature.
  • Primary extramedullary myeloid tumors (PEMMT) are extramedullary proliferations of myeloid cells occurring in the absence of an antecedent myeloproliferative disorder.
  • They have predilection for the skin, lymph nodes, central nervous system, and small intestine.
  • In addition, we present a new case of PEMMT of the breast who presented with a mass in her right breast mimicking a breast malignancy and was initially misdiagnosed as non-Hodgkin's lymphoma.
  • Treatment with systemic chemotherapy and local radiotherapy rendered a complete remission.
  • Most of the cases were misdiagnosed initially as lymphomas, breast carcinomas, or malignant melanomas.
  • PEMMT of the breast is a poorly recognized entity whose diagnosis frequently challenges both the pathologist and the oncologist.
  • Given the small number of patients reported no optimal treatment has been defined, but systemic chemotherapy similar to that given for acute myeloid leukemia with or without local radiotherapy may result in long remissions and avoid the progression to overt acute myeloid leukemia.
  • [MeSH-major] Breast Neoplasms / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Neoplasm Invasiveness. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12768322.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


28. Salamanca J, Nevado M, Martínez-González MA, Pérez-Espejo G, Pinedo F: Undifferentiated carcinoma of the jejunum with extensive rhabdoid features. Case report and review of the literature. APMIS; 2008 Oct;116(10):941-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant rhabdoid tumor, first described in the kidney of young infants, is a rare and highly aggressive neoplasm of controversial histogenesis that has been reported at many other sites, including the gastrointestinal tract.
  • However, malignant rhabdoid tumor of the small intestine is very rare, with only seven cases published to date.
  • Microscopically, the tumor was characterized by neoplastic cells with vesicular nuclei, large nucleoli and abundant eccentric cytoplasm with hyaline globular intracytoplasmic inclusions.
  • Immunohistochemically, the neoplasm coexpressed vimentin and epithelial antigens (AE1/AE3, Cam 5.2, CK34betaE12, CK19 and EMA), most of them showing a peculiar immunostaining pattern in relation to the globular inclusions.
  • The patient received postoperative chemotherapy but died 9 months after surgery.
  • As with tumors at other sites, recognition of rhabdoid morphology in small intestine neoplasms is of significance because the prognosis is extremely poor.
  • [MeSH-major] Carcinoma / pathology. Jejunal Neoplasms / pathology. Liver Neoplasms / secondary. Rhabdoid Tumor / pathology
  • [MeSH-minor] Aged. Anion Exchange Protein 1, Erythrocyte / analysis. Anion Exchange Protein 1, Erythrocyte / metabolism. Biomarkers / analysis. Biomarkers / metabolism. Biopsy. Cell Nucleolus / pathology. Fatal Outcome. Humans. Hyalin / metabolism. Immunohistochemistry. Inclusion Bodies / metabolism. Inclusion Bodies / pathology. Jejunum / metabolism. Jejunum / pathology. Keratins / analysis. Keratins / metabolism. Liver / pathology. Male. Neoplasm Proteins / analysis. Neoplasm Proteins / metabolism. Vimentin / analysis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19132990.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anion Exchange Protein 1, Erythrocyte; 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / CK-34 beta E12; 0 / Neoplasm Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 8
  •  go-up   go-down


29. Karatzoglou P, Karagiannidis A, Kountouras J, Christofiridis CV, Karavalaki M, Zavos C, Gavalas E, Patsiaoura K, Vougiouklis N: Von Recklinghausen's disease associated with malignant peripheral nerve sheath thmor presenting with constipation and urinary retention: a case report and review of the literature. Anticancer Res; 2008 Sep-Oct;28(5B):3107-13
MedlinePlus Health Information. consumer health - Constipation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Von Recklinghausen's disease associated with malignant peripheral nerve sheath thmor presenting with constipation and urinary retention: a case report and review of the literature.
  • A malignant peripheral nerve sheath tumor (MPNST) is a rare neoplasm arising from peripheral nerve sheaths.
  • We herein report the first case of MPNST originating from the left gluteal muscle region, diffusely extending into the adjacent small pelvis and perineum.
  • The patient had a family history of neurofibromatosis type 1.
  • A computed tomography scan revealed a giant tumor which displaced the bladder and segments of the intestine.
  • The histopathological diagnosis was MPNST.
  • The patient declined chemotherapy and radiation therapy and died 2 months later.
  • [MeSH-major] Constipation / etiology. Nerve Sheath Neoplasms / complications. Neurofibromatosis 1 / complications. Urinary Retention / etiology

  • Genetic Alliance. consumer health - Constipation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031965.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


30. Gong LS, Zhang YD, Liu S: Target distribution of magnetic albumin nanoparticles containing adriamycin in transplanted rat liver cancer model. Hepatobiliary Pancreat Dis Int; 2004 Aug;3(3):365-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Target distribution of magnetic albumin nanoparticles containing adriamycin in transplanted rat liver cancer model.
  • BACKGROUND: Liver cancer is one of the most common diseases around the world.
  • The aim of this study was to verify the effect of magnetic field application on target distribution of nanoparticles in transplanted rat liver cancer model and to find out a new method for the treatment of malignant liver tumor.
  • In the experimental group (12 rats), the tumor tissue was exposed to the magnetic field for 30 minutes.
  • Tissues of tumor, nontargeted sites of the liver, heart, kidney, lung, spleen, stomach and small intestine were analyzed for gamma-counts and examined histologically.
  • RESULTS: In the experimental group, the radioactivity of tumor tissue was 8.7 times that of liver tissue.
  • In the control group, the radioactivity of tumor tissue was 2.8 times that of normal liver tissue.
  • No significant difference in the kidney, heart, spleen, small intestine and stomach was observed between the experimental group and control group.
  • CONCLUSIONS: In the presence of magnetic field, magnetic albumin nanoparticles may accumulate in tumor tissues, of which the radioactivity can increase to 8.7 times that of normal liver.
  • Even if the magnetic field is not applied, magnetic albumin nanoparticles in tumor tissues still increase to 2.8 times that of normal liver tissues.
  • These findings indicate that normal organs in the presence of magnetic field are less exposed to chemotherapeutic drugs.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacokinetics. Carcinoma 256, Walker / drug therapy. Carcinoma, Hepatocellular / drug therapy. Doxorubicin / pharmacokinetics. Liver Neoplasms / drug therapy
  • [MeSH-minor] Albumins / pharmacokinetics. Animals. Disease Models, Animal. Electromagnetic Fields. Hepatic Artery. Magnetics. Male. Neoplasm Transplantation. Particle Size. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313670.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Albumins; 0 / Antimetabolites, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


31. Ulusan S, Koç Z, Kayaselçuk F: Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment. Turk J Gastroenterol; 2008 Jun;19(2):129-32
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment.
  • Our objective was to show the unusual imaging characteristics of cystic liver metastases from a malignant gastrointestinal stromal tumor before and after treatment with imatinib mesylate.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / ultrasonography. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Aged. Benzamides. Colon / pathology. Fatal Outcome. Humans. Imatinib Mesylate. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / ultrasonography. Intestine, Small / pathology. Liver / drug effects. Liver / pathology. Liver / ultrasonography. Male. Neoplasm Invasiveness. Stomach / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110671.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


32. Fu DL, Yang F, Maskay A, Long J, Jin C, Yu XJ, Xu J, Zhou ZW, Ni QX: Primary intestinal malignant fibrous histiocytoma: two case reports. World J Gastroenterol; 2007 Feb 28;13(8):1299-302
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intestinal malignant fibrous histiocytoma: two case reports.
  • Malignant fibrous histiocytoma (MFH) occurs most commonly in the extremities and trunk, but rarely in the intestine.
  • Here we report two cases of primary intestinal MFH.
  • At laparotomy, a tumor was found originating from the cecum, with a suspicious metastatic nodule on the surface of the right lobe of the liver.
  • The second case was a 43-year old man with intussusceptions of the small intestine.
  • An emergent laparotomy revealed 4 pedunculated masses in the small bowel and a partial resection of the small intestine was performed.
  • Though the symptoms were not typical, based on histological and immunohistochemical studies, the patients were diagnosed as MFH of the intestine.
  • They were not treated with chemotherapy or radiotherapy and both died within 3 mo.
  • MFH of the intestine is an extremely rare neoplasm with an aggressive biological behavior.
  • Complete surgical excision is preferred, adjuvant chemotherapy or radiotherapy may be advisable.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Intestinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Cecum / pathology. Fatal Outcome. Humans. Intestine, Small / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Burns. 2000 May;26(3):305-10 [10741601.001]
  • [Cites] Surg Today. 2005;35(4):323-7 [15815852.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Skeletal Radiol. 2003 Nov;32(11):613-8 [14517697.001]
  • [Cites] Dig Dis Sci. 2004 Aug;49(7-8):1156-60 [15387338.001]
  • [Cites] Burns. 2004 Nov;30(7):742-5 [15475153.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Exp Hematol. 1993 Sep;21(10):1342-52 [7689482.001]
  • [Cites] Gastroenterol Jpn. 1993 Aug;28(4):554-63 [7690726.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):91-6 [8548744.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):983-94 [8600111.001]
  • [Cites] Pathol Int. 1997 Oct;47(10):718-24 [9361108.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jan 15;100(2):134-42 [9428357.001]
  • [Cites] Surg Today. 1999;29(2):160-4 [10030742.001]
  • [Cites] Eur J Surg Oncol. 1999 Aug;25(4):447-8 [10419723.001]
  • [Cites] APMIS. 1999 Sep;107(9):837-42 [10519319.001]
  • [Cites] Mt Sinai J Med. 2005 Jan;72(1):50-2 [15682264.001]
  • [Cites] Surg Today. 2001;31(3):242-5 [11318129.001]
  • (PMID = 17451221.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4147015
  •  go-up   go-down


33. Kuroda K, Ishizawa S, Kudo T, Uotani H, Hosokawa A, Tanaka T, Kitano H, Hori T, Tsukada K, Sugiyama T, Fukuoka J: Localized malignant mesenteric mesothelioma causing small bowel obstruction. Pathol Int; 2008 Apr;58(4):239-43
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized malignant mesenteric mesothelioma causing small bowel obstruction.
  • Malignant mesothelioma is an uncommon lethal neoplasm in the serous membrane in which peritoneal mesothelioma is a rarer form.
  • Herein is reported a case of malignant mesothelioma presenting as a localized mass inside the mesentery causing focal luminal obstruction of the small intestine.
  • The diagnosis of malignant mesothelioma was obtained on repeat double balloon endoscopic biopsy.
  • Partial resection of the small intestine along with the mesentery was performed, followed by a course of chemotherapy.
  • To the best of the authors' knowledge this is the first reported case of localized malignant mesothelioma arising inside the mesentery.
  • Mesothelioma should be considered as the differential diagnosis when small bowel obstruction occurs with unknown primary neoplasm.
  • [MeSH-major] Intestinal Obstruction / pathology. Mesentery / pathology. Peritoneal Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Endoscopy, Gastrointestinal. Epithelioid Cells / pathology. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324917.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Croom KF, Perry CM: Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs; 2003;63(5):513-22; discussion 523-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
  • The KIT tyrosine kinase is abnormally expressed in gastrointestinal stromal tumour (GIST), a rare neoplasm for which there has been no effective systemic therapy.
  • Similar response rates were reported in a smaller, dose-escalation study, in which objective tumour response was a secondary endpoint.
  • Severe or serious adverse events occurred in 21% of patients in the larger study, and included gastrointestinal or tumour haemorrhage.
  • A major focus of cancer research in recent years has been to identify oncogenic molecules and the signal transduction pathways in which they are involved, in order to develop specifically targeted drugs.
  • One such drug is imatinib mesylate (imatinib, Glivic/Gleevec), an orally administered 2-phenylaminopyrimidine derivative that is a competitive inhibitor of the tyrosine kinases associated with platelet-derived growth factor (PDGF) receptors, the Abelson (ABL) protein and the KIT protein (also known as stem cell factor [SCF] receptor).
  • Imatinib was initially evaluated for the treatment of chronic myeloid leukaemia (CML) [reviewed previously in Drugs].
  • More recently, imatinib has been approved for the treatment of patients with advanced gastrointestinal stromal tumour (GIST), in which KIT, a tyrosine kinase receptor, is abnormally expressed.
  • GISTs are soft tissue gastrointestinal sarcomas probably arising from mesenchymal cells.
  • They are rare neoplasms, with between 5000 and 10 000 new cases being diagnosed each year in the US.
  • GISTs occur throughout the gastrointestinal tract but the stomach and small intestine are the most common sites.
  • Symptoms depend on the site and size of the tumour, and may include abdominal pain, gastrointestinal bleeding or signs of obstruction; small tumours may be asymptomatic.
  • The diagnosis of GIST is made by immunohistochemical staining for CD117, a cell surface antigen on the extracellular domain of KIT, in conjunction with pathological examination of tissue with light microscopy.
  • All GISTs may have some degree of malignant potential.
  • They are unresponsive to standard chemotherapy and to radiotherapy, and the mainstay of treatment in the past has been surgery.
  • However, recurrence rates are high, and there has been no effective systemic treatment for unresectable GIST or metastatic disease.
  • Gain-of-function mutations of the KIT proto-oncogene occur in up to 90% of GISTs, allowing constitutive activation of tyrosine kinase (i.e. auto-phosphorylation of tyrosine residues independent of ligand-receptor binding), leading to aberrant cell division and tumour growth.
  • This article summarises the pharmacology, efficacy and tolerability profile of imatinib in the treatment of patients with advanced GIST.
  • [MeSH-major] Antineoplastic Agents. Gastrointestinal Neoplasms / drug therapy. Piperazines. Pyrimidines. Stromal Cells / pathology
  • [MeSH-minor] Benzamides. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacokinetics. Enzyme Inhibitors / pharmacology. Enzyme Inhibitors / therapeutic use. Humans. Imatinib Mesylate. Multicenter Studies as Topic. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2001 Jun;32(6):578-82 [11431711.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):5054-8 [11526490.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):485-91 [12057094.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Anticancer Drugs. 2002 Sep;13(8):847-9 [12394270.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 20;91(2):163-8 [9923858.001]
  • [Cites] Blood. 2000 Aug 1;96(3):925-32 [10910906.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Science. 2000 Sep 15;289(5486):1938-42 [10988075.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3898-905 [12228211.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5143-50 [11016641.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3319-26 [10955819.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5 Suppl 17):3-8 [11740801.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):683-93 [11870247.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] J Clin Invest. 2000 Jan;105(1):3-7 [10619854.001]
  • [Cites] Ann Surg. 1987 Dec;206(6):706-10 [3689007.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3719-23 [10446987.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4947-52 [9389713.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5778-83 [11479215.001]
  • [Cites] Biochim Biophys Acta. 1997 Dec 9;1333(3):F217-48 [9426205.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 [10991971.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4879-83 [12208734.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Drugs. 2001;61(12):1765-74; discussion 1775-6 [11693465.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7 [12528778.001]
  • (PMID = 12600228.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 45
  •  go-up   go-down






Advertisement